|
|
Phase III Trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic oncology group study. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. J Clin Oncol 2003; 21: 3194-3200.
|
|
|
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. NEJM. 2002: 346 (21) : 1609-15. http://www.ncbi.nlm.nih.gov/pubmed/12023992 http://www.nejm.org/doi/full/10.1056/NEJMoa020119 Free Full Text
|